Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

CD133 (Prominin) negative human neural stem cells are clonogenic and tripotent.

Sun Y, Kong W, Falk A, Hu J, Zhou L, Pollard S, Smith A.

PLoS One. 2009;4(5):e5498. doi: 10.1371/journal.pone.0005498. Epub 2009 May 11.

2.

PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells.

Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC.

Cell Stem Cell. 2009 Mar 6;4(3):226-35. doi: 10.1016/j.stem.2009.01.007.

3.

Tumor-associated galectin-3 modulates the function of tumor-reactive T cells.

Peng W, Wang HY, Miyahara Y, Peng G, Wang RF.

Cancer Res. 2008 Sep 1;68(17):7228-36. doi: 10.1158/0008-5472.CAN-08-1245.

4.

Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas.

Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Sun W, Qiao W, Hiraoka N, Fuller GN.

Clin Cancer Res. 2008 Aug 15;14(16):5166-72. doi: 10.1158/1078-0432.CCR-08-0320.

5.

Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.

Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, Hainfellner JA, Heppner FL, Dietrich PY, Zimmer Y, Cairncross JG, Janzer RC, Domany E, Delorenzi M, Stupp R, Hegi ME.

J Clin Oncol. 2008 Jun 20;26(18):3015-24. doi: 10.1200/JCO.2007.15.7164.

PMID:
18565887
6.

CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors.

Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, Chadburn A, Murphy AJ, Valenzuela DM, Gale NW, Thurston G, Yancopoulos GD, D'Angelica M, Kemeny N, Lyden D, Rafii S.

J Clin Invest. 2008 Jun;118(6):2111-20. doi: 10.1172/JCI34401.

7.

Chemicals that modulate stem cell differentiation.

Hwang KC, Kim JY, Chang W, Kim DS, Lim S, Kang SM, Song BW, Ha HY, Huh YJ, Choi IG, Hwang DY, Song H, Jang Y, Chung N, Kim SH, Kim DW.

Proc Natl Acad Sci U S A. 2008 May 27;105(21):7467-71. doi: 10.1073/pnas.0802825105. Epub 2008 May 14.

8.

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.

Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringdén O; Developmental Committee of the European Group for Blood and Marrow Transplantation.

Lancet. 2008 May 10;371(9624):1579-86. doi: 10.1016/S0140-6736(08)60690-X.

PMID:
18468541
9.

Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells.

Wei J, Duramad O, Perng OA, Reiner SL, Liu YJ, Qin FX.

Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):18169-74. Epub 2007 Oct 31.

10.

A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients.

Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I, Priebe W, Heimberger AB.

Cancer Res. 2007 Oct 15;67(20):9630-6.

11.

Galectin-1 expression in human glioma cells: modulation by ionizing radiation and effects on tumor cell proliferation and migration.

Strik HM, Schmidt K, Lingor P, Tönges L, Kugler W, Nitsche M, Rabinovich GA, Bähr M.

Oncol Rep. 2007 Aug;18(2):483-8.

PMID:
17611674
12.

Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells.

Ghods AJ, Irvin D, Liu G, Yuan X, Abdulkadir IR, Tunici P, Konda B, Wachsmann-Hogiu S, Black KL, Yu JS.

Stem Cells. 2007 Jul;25(7):1645-53. Epub 2007 Apr 5.

13.

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.

Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, Mischel PS, Stokoe D, Pieper RO.

Nat Med. 2007 Jan;13(1):84-8. Epub 2006 Dec 10.

PMID:
17159987
14.

Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells.

Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco F, Vescovi AL.

Nature. 2006 Dec 7;444(7120):761-5.

PMID:
17151667
15.

Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma.

Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS.

Mol Cancer. 2006 Dec 2;5:67.

16.

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN.

Nature. 2006 Dec 7;444(7120):756-60. Epub 2006 Oct 18.

PMID:
17051156
17.

Successful therapy must eradicate cancer stem cells.

Dingli D, Michor F.

Stem Cells. 2006 Dec;24(12):2603-10. Epub 2006 Aug 24.

18.

Multipotent, dedifferentiated cancer stem-like cells from brain gliomas.

Kang SK, Park JB, Cha SH.

Stem Cells Dev. 2006 Jun;15(3):423-35. Erratum in: Stem Cells Dev. 2006 Oct;15(5):749.

PMID:
16846378
19.
20.

Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma.

Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, Herndon JE 2nd, Bigner DD, Dranoff G, Sampson JH.

Cancer Res. 2006 Mar 15;66(6):3294-302.

Supplemental Content

Support Center